Dixon Q1 FY27 PAT jumps 156% YoY to Rs 718 cr on consolidated basis

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF Explain this filing

DIXON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹14321.00

prior close

₹14363.00

announcement price

In-mkt

timing

Nifty Midcap 150market+0.5%-4.4% vs market

Consumer Electronics peers, median of 13sector-1.3%-2.7% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Midcap 150 and 2.7 pts less than its Consumer Electronics peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.0

10m

-4.7

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0+0.5-4.4-1.3-2.7

Next day

-3.0+1.7-4.7+0.7-3.7

-2.9+1.4-4.3+0.2-3.0

+0.3+1.6-1.3-0.2+0.4

-0.8+1.2-2.1-0.5-0.3

-1.1+1.4-2.6-0.2-0.9

-2.1+1.9-3.9-0.6-1.5

15d

+3.7+1.6+2.1-2.9+6.6

+3.7+2.2+1.5-3.6+7.2

-8.5-5.1-3.5-13.6+5.1

—————

UpDownMarket · Nifty Midcap 150Sector · Consumer Electronics peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dixon Technologies Q1 FY27 consolidated: PAT up 156% YoY at Rs 718 cr, revenue up 25% at Rs 16,076 cr, EBITDA up 105% at Rs 991 cr and PBT up 137% at Rs 869 cr. Board re-appointed promoter Sunil Vachani and MD Atul Lall for 5 more years from May 2027. Auditors flagged that a subsidiary recognized Rs 1,110 cr PLI incentive income pending PMA approval. Granted 4,000 ESOP options. Final dividend of Rs 10 per share for FY26.

Likely market impact

Strong across-the-board growth and leadership continuity are positive, but Rs 1,110 cr PLI recognition pending PMA approval remains a key risk.